Article | June 18, 2026

How AstraZeneca Is Managing Their Extractables And Leachables Data

Source: ACD/Labs

By Jesse Harris, Digital Marketing Coordinator, ACD/Labs

enzymes-drug-conjugte-GettyImages-1343098807

Container-closure systems are easy to overlook, but their materials can interact with medicines in ways that impact safety and efficacy. Extractables and leachables (E&L) research brings together chemistry, toxicology, and materials science to identify and mitigate these risks. Yet scientists often face fragmented data spread across formats and organizations, slowing progress. A collaborative effort within the ELSIE consortium has led to a searchable, pre‑competitive knowledge base designed to standardize and share E&L insights. With perspective from AstraZeneca’s Stephen Warren, explore how this resource is shaping better decision-making, improving data accessibility, and advancing safer pharmaceutical development practices.

Read the full article to discover how unified knowledge can reduce uncertainty and accelerate your E&L workflows.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online